Explore the words cloud of the MCBD project. It provides you a very rough idea of what is the project "MCBD" about.
The following table provides information about the project.
SOREK MEDICAL SYSTEMS LTD
|Coordinator Country||Israel [IL]|
|Total cost||2˙290˙000 €|
|EC max contribution||1˙603˙000 € (70%)|
1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
|Duration (year-month-day)||from 2019-10-01 to 2021-09-30|
Take a look of project's partnership.
|1||SOREK MEDICAL SYSTEMS LTD||IL (YOKNEAM ILLIT)||coordinator||1˙603˙000.00|
Biopsy is a commonly used medical procedure for the diagnosis and characterization of cancer and other diseases. Traditionally, the tissue obtained is preserved by formalin fixation, embedded in paraffin, sectioned to thin tissue layers, and then analysed histologically under the microscope to evaluat overall tissue morphology. Current advancement in biomedicine makes it possible for greater use of molecular technologies. These technologies, allow for analysis of change in biomolecules (biomarkers) during cancer progression rather than tissue morphology alone. Laboratory analysis of biomarkers require tissue to be fresh (or fresh frozen) and rather not be preserved by formalin. In order to yield viable biomarker analysis tissue must be frozen as soon as possible because biomarkers are extremely sensitive to degradation. Current biopsy devices are not designed to meet these challenges of rapid freezing as a replacement to formalin fixation. We, at Sorek Medical Systems Ltd., a 16-year-old R&D company based in Israel, developed two biopsy devices that automatically split the tissue sample in two during biopsy acquisition. Our technology allows simultaneous chemical standard formalin fixation (for histology) and freezing preservation (for molecular analysis). Sorek’s devices will be used by radiologists and surgeons, and by pharmaceutical companies seeking the development of biomarker-targeting drugs with the goal of improving personalized medicine and improving early diagnosis for breast, lung, chest, prostate, and other organs’ cancer disease. Our CryoBiopsy Phase 2 project will allow us to test and validate our devices which will require € 2.8 million investment. Our financial forecast show that after five-year commercialization we will generate a cumulative revenues of €57 million and will create 20 positions which will include engineers, technicians and our own sales personnel
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MCBD" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "MCBD" are provided by the European Opendata Portal: CORDIS opendata.
Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any contRead More
COMMERCIALIZING THE FIRST HEAD-UP-DISPLAY FOR OFF-HIGHWAY VEHICLESRead More
Carbon Offset Plug-inRead More